Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients

Affiliations

¹ Private Dermatology Practice, Bellinzona/Lugano, Switzerland. Electronic address: matildeiorizzo@gmail.com.
² Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Italy.
³ Trichology Unit, Dermatology Department, Ramón y Cajal Hospital, IRYCS, University of Alcala, Madrid, Spain.
⁴ Centre Sabouraud, Saint-Louis Hospital, Paris, France.
⁵ Department of Dermatology, Medical University of Warsaw, Poland.
⁶ Hair Treatment and Transplantation Center, Saint Petersburg, Russia.
⁷ Sinclair Dermatology, Melbourne, Australia.
⁸ Department of Dermatology, Miller School of Medicine, Miami, Florida.

Matilde Iorizzo et al. J Am Acad Dermatol. 2022 Sep.

. 2022 Sep;87(3):666-669.

doi: 10.1016/j.jaad.2022.02.044. Epub 2022 Mar 1.

¹ Private Dermatology Practice, Bellinzona/Lugano, Switzerland. Electronic address: matildeiorizzo@gmail.com.
² Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Italy.
³ Trichology Unit, Dermatology Department, Ramón y Cajal Hospital, IRYCS, University of Alcala, Madrid, Spain.
⁴ Centre Sabouraud, Saint-Louis Hospital, Paris, France.
⁵ Department of Dermatology, Medical University of Warsaw, Poland.
⁶ Hair Treatment and Transplantation Center, Saint Petersburg, Russia.
⁷ Sinclair Dermatology, Melbourne, Australia.
⁸ Department of Dermatology, Miller School of Medicine, Miami, Florida.

No abstract available

Keywords: adalimumab; biologics; cicatricial alopecia; folliculitis decalvans; hair disorders; hair loss; scarring alopecia; treatment.

Conflict of interest statement

Conflicts of interest None disclosed.